Hammond, Edward
Haynes, Nicole M.
Cullinane, Carleen
Brennan, Todd V.
Bampton, Darryn
Handley, Paul
Karoli, Tomislav
Lanksheer, Fleur
Lin, Liwen
Yang, Yiping
Dredge, Keith http://orcid.org/0000-0001-7243-560X
Article History
Received: 23 April 2018
Accepted: 21 May 2018
First Online: 14 June 2018
Ethics approval
: For the route of administration studies in mice, experiments were done in accordance with protocols approved by the Animal Care and Use Committee of Duke University. The 4 T1.2 syngeneic tumor model study was performed with approval of the Peter MacCallum Cancer Centre Animal Experimentation Ethics Committee.For the toxicology study, procedures involving the care and use of animals in this study were reviewed and approved by the Institutional Animal Care and Use Committee (IACUC). During the study, the care and use of animals were conducted in accordance with the relevant principles currently used with regard to animal welfare. CiToxLAB Hungary Ltd.’s facility is AAALAC accredited. The PG545102 study was approved by local human research ethics committees (HREC), the Royal Adelaide Hospital Research Ethics Committee (for RAH site) and Bellberry Limited (for the sites at Linear and Nucleus Network). The trial was conducted in accordance with the ICH Good Clinical Practice (GCP) guidelines and the Declaration of Helsinki. All patients provided written informed consent.
: EH, PH, DB, TK, FL and KD were or are employees of Progen Pharmaceuticals or Zucero Therapeutics. DB receives consultancy fees from Zucero Therapeutics. NMH, CC, TVB, LL and YY declare that they have no competing interests.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.